Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1975 4
1976 5
1977 5
1978 1
1979 2
1980 2
1981 3
1982 1
1983 2
1984 8
1985 8
1986 6
1987 9
1988 4
1989 10
1990 14
1991 11
1992 15
1993 9
1994 8
1995 10
1996 11
1997 13
1998 10
1999 17
2000 15
2001 11
2002 16
2003 17
2004 11
2005 12
2006 13
2007 20
2008 16
2009 24
2010 14
2011 16
2012 15
2013 18
2014 26
2015 18
2016 17
2017 17
2018 25
2019 30
2020 25
2021 21
2022 13
2023 14
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

569 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Metastatic Malignant Neoplasm in the Uterine Cervix"
Page 1
Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.
Koh WJ, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR, Chon HS, Chu C, Clark R, Cohn D, Crispens MA, Damast S, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, Han E, Huh WK, Lurain JR, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Fader AN, Remmenga SW, Reynolds RK, Tillmanns T, Ueda S, Wyse E, Yashar CM, McMillian NR, Scavone JL. Koh WJ, et al. J Natl Compr Canc Netw. 2019 Jan;17(1):64-84. doi: 10.6004/jnccn.2019.0001. J Natl Compr Canc Netw. 2019. PMID: 30659131
Cervical cancer is a malignant epithelial tumor that forms in the uterine cervix. Most cases of cervical cancer are preventable through human papilloma virus (HPV) vaccination, routine screening, and treatment of precancerous lesions. ...This manuscript discu …
Cervical cancer is a malignant epithelial tumor that forms in the uterine cervix. Most cases of cervical cancer are pre …
Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study.
Simms KT, Steinberg J, Caruana M, Smith MA, Lew JB, Soerjomataram I, Castle PE, Bray F, Canfell K. Simms KT, et al. Lancet Oncol. 2019 Mar;20(3):394-407. doi: 10.1016/S1470-2045(18)30836-2. Epub 2019 Feb 19. Lancet Oncol. 2019. PMID: 30795950
We then used a comprehensive and extensively validated simulation platform, Policy1-Cervix, to do a dynamic multicohort modelled analysis of the impact of potential scale-up scenarios for cervical cancer prevention, in order to predict the future incidence rates and burden …
We then used a comprehensive and extensively validated simulation platform, Policy1-Cervix, to do a dynamic multicohort modelled anal …
Phase I study of adjuvant immunotherapy with autologous tumor-infiltrating lymphocytes in locally advanced cervical cancer.
Huang H, Nie CP, Liu XF, Song B, Yue JH, Xu JX, He J, Li K, Feng YL, Wan T, Zheng M, Zhang YN, Ye WJ, Li JD, Li YF, Li JY, Cao XP, Liu ZM, Zhang XS, Liu Q, Zhang X, Liu JH, Li J. Huang H, et al. J Clin Invest. 2022 Aug 1;132(15):e157726. doi: 10.1172/JCI157726. J Clin Invest. 2022. PMID: 35727633 Free PMC article. Clinical Trial.
BACKGROUNDAdoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) has achieved remarkable clinical efficacy in metastatic cancers such as melanoma and cervical cancer (CC). Here, we explored the safety, feasibility, and preliminary tumor response and …
BACKGROUNDAdoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) has achieved remarkable clinical efficacy in meta …
Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model.
Jin BY, Campbell TE, Draper LM, Stevanović S, Weissbrich B, Yu Z, Restifo NP, Rosenberg SA, Trimble CL, Hinrichs CS. Jin BY, et al. JCI Insight. 2018 Apr 19;3(8):e99488. doi: 10.1172/jci.insight.99488. eCollection 2018 Apr 19. JCI Insight. 2018. PMID: 29669936 Free PMC article. Clinical Trial.
We identified an HPV-16 E7-specific, HLA-A*02:01-restricted TCR from a uterine cervix biopsy from a woman with cervical intraepithelial neoplasia. ...These findings support the therapeutic potential of this approach and established the basis for an E7 TCR gene thera …
We identified an HPV-16 E7-specific, HLA-A*02:01-restricted TCR from a uterine cervix biopsy from a woman with cervical intrae …
Immunotherapy in cervix cancer.
Attademo L, Tuninetti V, Pisano C, Cecere SC, Di Napoli M, Tambaro R, Valabrega G, Musacchio L, Setola SV, Piccirillo P, Califano D, Spina A, Losito S, Greggi S, Pignata S. Attademo L, et al. Cancer Treat Rev. 2020 Nov;90:102088. doi: 10.1016/j.ctrv.2020.102088. Epub 2020 Aug 7. Cancer Treat Rev. 2020. PMID: 32827839 Review.
The treatment approach to cervix cancer has remained unchanged for several decades and new therapeutic strategies are now required to improve outcomes, as the prognosis is still poor. ...We reviewed the published data and the therapeutic implications of the most promising …
The treatment approach to cervix cancer has remained unchanged for several decades and new therapeutic strategies are now required to …
Incidence of adverse events in minimally invasive vs open radical hysterectomy in early cervical cancer: results of a randomized controlled trial.
Obermair A, Asher R, Pareja R, Frumovitz M, Lopez A, Moretti-Marques R, Rendon G, Ribeiro R, Tsunoda A, Behan V, Buda A, Bernadini MQ, Zhao H, Vieira M, Walker J, Spirtos NM, Yao S, Chetty N, Zhu T, Isla D, Tamura M, Nicklin J, Robledo KP, Gebski V, Coleman RL, Salvo G, Ramirez PT. Obermair A, et al. Am J Obstet Gynecol. 2020 Mar;222(3):249.e1-249.e10. doi: 10.1016/j.ajog.2019.09.036. Epub 2019 Oct 3. Am J Obstet Gynecol. 2020. PMID: 31586602 Free PMC article. Clinical Trial.
STUDY DESIGN: The Laparoscopic Approach to Carcinoma of the Cervix trial was a multinational, randomized noninferiority trial that was conducted between 2008 and 2017, in which surgeons from 33 tertiary gynecologic cancer centers in 24 countries ran …
STUDY DESIGN: The Laparoscopic Approach to Carcinoma of the Cervix trial was a multinational, randomized noninferiority …
Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses From the KEYNOTE-826 Randomized Clinical Trial.
Tewari KS, Colombo N, Monk BJ, Dubot C, Cáceres MV, Hasegawa K, Shapira-Frommer R, Salman P, Yañez E, Gümüs M, Olivera Hurtado de Mendoza M, Samouëlian V, Castonguay V, Arkhipov A, Tekin C, Li K, Toker S, Keefe SM, Lorusso D. Tewari KS, et al. JAMA Oncol. 2024 Feb 1;10(2):185-192. doi: 10.1001/jamaoncol.2023.5410. JAMA Oncol. 2024. PMID: 38095881 Clinical Trial.
IMPORTANCE: The KEYNOTE-826 randomized clinical trial showed statistically significant and clinically meaningful survival benefits with the addition of pembrolizumab to chemotherapy with or without bevacizumab in patients with persistent, recurrent, or met …
IMPORTANCE: The KEYNOTE-826 randomized clinical trial showed statistically significant and clinically meaningful surviv …
Balstilimab and other immunotherapy for recurrent and metastatic cervical cancer.
Bose CK. Bose CK. Med Oncol. 2022 Jan 29;39(4):47. doi: 10.1007/s12032-022-01646-7. Med Oncol. 2022. PMID: 35092506 Review.
Recurrent and metastatic cervical cancer is generally treated by cisplatin, paclitaxel, and bevacizumab with limited benefit this constituting an unmet need. ...It is used in other cancers and is currently proposed for cancer cervix also. Search is on for single or …
Recurrent and metastatic cervical cancer is generally treated by cisplatin, paclitaxel, and bevacizumab with limited benefit this con …
Chemotherapy and targeted therapy in the management of cervical cancer.
Kumar L, Harish P, Malik PS, Khurana S. Kumar L, et al. Curr Probl Cancer. 2018 Mar-Apr;42(2):120-128. doi: 10.1016/j.currproblcancer.2018.01.016. Epub 2018 Feb 3. Curr Probl Cancer. 2018. PMID: 29530393 Review.
Treatment with bevacizumab (an inhibitor of vascular endothelial growth factor) along with chemotherapy is associated with improved survival in patients with recurrent or metastatic cervical cancer. Weekly paclitaxel and carboplatin for 4-6 weeks as dose dense chemotherapy …
Treatment with bevacizumab (an inhibitor of vascular endothelial growth factor) along with chemotherapy is associated with improved survival …
Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial.
Ogilvie GS, van Niekerk D, Krajden M, Smith LW, Cook D, Gondara L, Ceballos K, Quinlan D, Lee M, Martin RE, Gentile L, Peacock S, Stuart GCE, Franco EL, Coldman AJ. Ogilvie GS, et al. JAMA. 2018 Jul 3;320(1):43-52. doi: 10.1001/jama.2018.7464. JAMA. 2018. PMID: 29971397 Free PMC article. Clinical Trial.
OBJECTIVE: To evaluate histologically confirmed cumulative incident cervical intraepithelial neoplasia (CIN) grade 3 or worse (CIN3+) detected up to and including 48 months by primary HPV testing alone (intervention) or liquid-based cytology (control). DESIGN, SETTING, AND PARTIC …
OBJECTIVE: To evaluate histologically confirmed cumulative incident cervical intraepithelial neoplasia (CIN) grade 3 or worse (CIN3+) detect …
569 results